Methylene Blue

Mechanism

Pharmacological Group and Molecular Target

Exogenous electron acceptor with cofactor-dependent oxidation-reduction properties.

Detailed Mechanism of Action

Functional hemoglobin contains iron in the ferrous state (Fe²⁺). Certain exogenous oxidizing agents (such as nitrites, benzocaine, dapsone or aniline) oxidize iron to the ferric state (Fe³⁺), transforming the molecule into methemoglobin, which is completely incapable of transporting and releasing molecular oxygen to the body's tissues, shifting the dissociation curve to the left and causing severe tissue hypoxia and cyanosis refractory to oxygen therapy.

Methylene blue is a chemical cofactor that is rapidly reduced by the erythrocyte enzyme NADPH-methemoglobin reductase to form leukocomethylene blue. This latter compound acts as a potent and specific electron donor, non-enzymatically reducing the ferric iron of methemoglobin back to the functional ferrous state:

Pharmacokinetics

Pharmacokinetic and Toxicokinetic Profile

• Distribution: It is selectively concentrated in the erythrocyte parenchyma. It has a wide distribution in peripheral tissues.
• Metabolism: Almost completely reduced in red blood cells to leukocomethylene blue, which remains in a soluble state.
• Excretion: Renal, temporarily giving a blue-greenish color to the patient's urine.
• Elimination half-life: Between 5 and 6 hours.

Indicators and dose

Specific Clinical Indications

• Symptomatic treatment of methemoglobinemia of acquired origin when the serum methemoglobin fraction exceeds 30%, or at lower levels if the patient presents symptoms of tissue hypoxia (dyspnea, chest pain, obtundation, lactic acidosis).

Dosage Scheme and Infusion Protocols

• Standard Dose: Administer 1 mg/kg to 2 mg/kg IV of a 1% solution infused over a period of 5 to 10 minutes slowly.
• If cyanosis does not resolve within 60 minutes, a second single dose of 1 mg/kg may be repeated.
• Maximum recommended cumulative dose: 7 mg/kg; Exceeding this limit can induce iatrogenic methemoglobinemia and severe hemolysis due to direct oxidative toxicity of the antidote.

Security

Absolute Contraindication in G6PD Deficiency

Methylene blue is strictly contraindicated in patients with deficiency of the enzyme glucose-6-phosphate dehydrogenase (G6PD). In these patients, the inability to generate NADPH via the pentose phosphate pathway blocks the conversion of methylene blue to leukocomethylene blue. The accumulated unreduced methylene blue paradoxically acts as a potent oxidizing agent, triggering uncontrollable massive intravascular hemolysis with further worsening of systemic hypoxia.